William Blair & Company
RGLS

William Blair & Company’s Regulus Therapeutics RGLS Stock Holding History

William Blair & Company’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,120
Closed -$3K – 1920
2022
Q1 		$3K Buy
1,120
+50
+5% +$130 ﹤0.01% 1880
2021
Q4 		$3K Hold
1,070
– – ﹤0.01% 1937
2021
Q3 		$7K Hold
1,070
– – ﹤0.01% 1816
2021
Q2 		$9K Hold
1,070
– – ﹤0.01% 1823
2021
Q1 		$17K Sell
1,070
-50
-4% -$740 ﹤0.01% 1758
2020
Q4 		$15K Hold
1,120
– – ﹤0.01% 1719
2020
Q3 		$6K Hold
1,120
– – ﹤0.01% 1662
2020
Q2 		$8K Hold
1,120
– – ﹤0.01% 1606
2020
Q1 		$5K Buy
1,120
+100
+10% +$872 ﹤0.01% 1593
2019
Q4 		$9K Hold
1,020
– – ﹤0.01% 1643
2019
Q3 		$7K Buy
1,020
+13
+1% +$106 ﹤0.01% 1625
2019
Q2 		$13K Hold
1,007
– – ﹤0.01% 1620
2019
Q1 		$10K Buy
+1,007
New +$11K ﹤0.01% 1621

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair & Company's RGLS Position: Q2 2022 in Review

William Blair & Company sold out of Regulus Therapeutics (RGLS) in Q2 2022, closing a stake of 1,120 shares — an estimated $3K sold.

William Blair & Company first reported a position in RGLS in Q1 2019 and held it in 13 quarters. The position peaked at $17K in Q1 2021. 27 funds tracked by Wall St. Rank hold RGLS as of Q2 2022.

  • William Blair & Company reported no remaining Regulus Therapeutics position as of Q2 2022 after selling out during the quarter.
  • William Blair & Company sold 1,120 Regulus Therapeutics shares in Q2 2022, an estimated $3K.
  • William Blair & Company first reported a position in Regulus Therapeutics in Q1 2019 and held it in 13 quarters.
  • William Blair & Company's Regulus Therapeutics position peaked at $17K in Q1 2021.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2022.

Based on William Blair & Company's 13F filing for Q2 2022, filed 10 Aug 2022.